Entering text into the input field will update the search result below

Gilead Sciences (NASDAQ:GILD) says the FDA has approved StribildT, a complete once-daily single...

Aug. 27, 2012 5:30 PM ETGilead Sciences, Inc. (GILD) StockGILDBy: David Yelle, SA News Editor

Gilead Sciences (NASDAQ:GILD) says the FDA has approved StribildT, a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. The drug - once referred to as the "Quad" prior to FDA approval - is a co-formulated HIV medicine that simplifies therapy by combining four compounds into one daily tablet. Shares +0.7% AH.

Recommended For You

More Trending News

About GILD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GILD--
Gilead Sciences, Inc.